BioVie (BIVI) vs Chemomab Therapeutics (CMMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Chemomab Therapeutics (CMMB) over the past year, losing 35.0% versus a loss of 60.3%. Over five years, CMMB leads with a -96.2% price change compared with -99.8% for BIVI. BioVie is the larger company by market cap ($12.1 million vs $10.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | CMMB |
|---|---|---|
| Share price | $1.39 | $1.38 |
| Market cap | $12.07M | $10.11M |
| 1-day change | +8.59% | -0.72% |
| YTD return | +10.34% | -15.76% |
| 1-year return | -35.03% | -60.29% |
| 5-year return | -99.78% | -96.18% |
| EPS (TTM) | $-3.05 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $3.50 |
| 52-week low | $0.82 | $1.05 |
| Distance from 52-week high | -63.32% | -60.57% |
| Analyst consensus | none | none |
| Avg. price target upside | +278.42% | +262.32% |
| Average volume | 4.60M | 113.36K |
| Shares outstanding | 8.68M | 7.33M |
| Employees | 13 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed CMMB by 25.3 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
BIVI vs CMMB FAQ
Which is bigger, BioVie or Chemomab Therapeutics?
BioVie (BIVI) is larger, with a market capitalization of $12.07M compared with $10.11M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, BIVI or CMMB?
BIVI returned -35.03% over the past 12 months, compared with -60.29% for CMMB (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Chemomab Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.